These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 15938923)
1. [Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma]. Yu BM; Wu WQ Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):557-60. PubMed ID: 15938923 [TBL] [Abstract][Full Text] [Related]
2. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6. Choi CK; Chan RT; Tung SY; Lui L; Siu S; Au GK; Ho JW; Law WL Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):168-75. PubMed ID: 18155454 [TBL] [Abstract][Full Text] [Related]
4. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. Li W; Xu J; Shen L; Liu T; Guo W; Zhang W; Chen Z; Zhu X; Li J BMC Cancer; 2014 Dec; 14():986. PubMed ID: 25527007 [TBL] [Abstract][Full Text] [Related]
6. First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study. Assy N; Basher W; Chetver L; Shnaider J; Zidan J J Clin Gastroenterol; 2012 Apr; 46(4):e27-30. PubMed ID: 22392022 [TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. Haller DG; Rothenberg ML; Wong AO; Koralewski PM; Miller WH; Bodoky G; Habboubi N; Garay C; Olivatto LO J Clin Oncol; 2008 Oct; 26(28):4544-50. PubMed ID: 18824706 [TBL] [Abstract][Full Text] [Related]
8. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. Hofheinz RD; Gnad-Vogt U; Wein A; Saussele S; Kreil S; Pilz L; Hehlmann R; Hochhaus A Anticancer Drugs; 2005 Jan; 16(1):39-45. PubMed ID: 15613902 [TBL] [Abstract][Full Text] [Related]
9. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039 [TBL] [Abstract][Full Text] [Related]
10. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Köhne CH; De Greve J; Hartmann JT; Lang I; Vergauwe P; Becker K; Braumann D; Joosens E; Müller L; Janssens J; Bokemeyer C; Reimer P; Link H; Späth-Schwalbe E; Wilke HJ; Bleiberg H; Van Den Brande J; Debois M; Bethe U; Van Cutsem E Ann Oncol; 2008 May; 19(5):920-6. PubMed ID: 18065406 [TBL] [Abstract][Full Text] [Related]
11. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304 [TBL] [Abstract][Full Text] [Related]
12. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. Choi DR; Yoon SN; Kim HS; Kim JH; Kim KY; Kim BC; Choi YK; Kim JB; Han B; Song HH; Zang DY Cancer Chemother Pharmacol; 2015 Mar; 75(3):639-43. PubMed ID: 25630415 [TBL] [Abstract][Full Text] [Related]
14. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. Hofheinz R; Hartung G; Samel S; Emig M; Pilz L; Willeke F; Hochhaus A; Hehlmann R; Queisser W Anticancer Drugs; 2002 Nov; 13(10):999-1004. PubMed ID: 12439333 [TBL] [Abstract][Full Text] [Related]
15. Current status of capecitabine in the treatment of colorectal cancer. Rothenberg ML Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635 [TBL] [Abstract][Full Text] [Related]
16. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Santini D; Vincenzi B; La Cesa A; Caricato M; Schiavon G; Spalletta B; Di Seri M; Coppola R; Rocci L; Tonini G Oncology; 2005; 69(1):27-34. PubMed ID: 16088232 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer. Heras P; Kritikos K; Hatzopoulos A; Xourafas V; Kritikos N; Karagiannis S; Mitsibounas D Am J Ther; 2009; 16(4):319-22. PubMed ID: 19352139 [TBL] [Abstract][Full Text] [Related]
18. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167 [TBL] [Abstract][Full Text] [Related]
19. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L Oncology; 2004; 66(5):371-8. PubMed ID: 15331924 [TBL] [Abstract][Full Text] [Related]
20. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Pasinetti N; Marini G Oncology; 2005; 69(4):283-9. PubMed ID: 16282707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]